HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Osler, A. G. Articles by Sandberg, A. L. Search for Related Content PubMed Articles by Osler, A. G. Articles by Sandberg, A. L.

The Fixation of Guinea Pig Complement by ₁ and ₂ Immunoglobulins¹

From the Department of Medical Immunology, The Public Health Research Institute of the City of New York, and the Department of Microbiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract

Several years ago the 7 S guinea pig immunoglobulins were separated into two well-defined electrophoretic classes: the slowly migrating 2 and the more rapid 1 (1–3). This achievement led to further studies which demonstrated that the ability to activate the complement (C') sequence was confined to 2 immunoglobulins. These antibodies failed to mediate passive cutaneous anaphylaxis (PCA) in the guinea pig. In contrast, the 1 immunoglobulins were capable of eliciting PCA reactions despite their purported deficiency in C'-fixing potency.

We have re-investigated this question and have confirmed all the previous findings excepting the C'-fixing properties of 1 type antibodies. These immunoglobulins do interact with guinea pig C' components, but probably by a different pathway.

Hartley strain guinea pigs were immunized with highly substituted dinitrophenylated bovine globulin (4) emulsified in complete Freund's adjuvant as described in (5). Initially, 250 µg of antigen were injected into each of the four toepads.

Footnotes

Support for this investigation was provided, in part, by the National Science Foundation. Grant GB-1120; The American Cancer Society, Inc., Grant T-257; The National Institute of Allergy and Infectious Diseases of the United States Public Health Service, Grant AI-03151; and the Office of The Surgeon General, Department of the Army, under the auspices of the Commission on Immunization of the Armed Forces Epidemiological Board, Contract DA-49-193-MD-2468.

² Department of Medical Immunology, The Public Health Research Institute of New York, N. Y.

³ Department of Microbiology, The Johns Hopkins University School of Medicine, Baltimore, Md.